Literature DB >> 27358350

Predominance of Lactobacillus spp. Among Patients Who Do Not Acquire Multidrug-Resistant Organisms.

Rafael Araos1, Albert K Tai2, Graham M Snyder3, Martin J Blaser4, Erika M C D'Agata5.   

Abstract

BACKGROUND: The emergence and dissemination of multidrug-resistant organisms (MDROs) is a global threat. Characterizing the human microbiome among hospitalized patients and identifying unique microbial signatures among those patients who acquire MDROs may identify novel infection prevention strategies.
METHODS: Adult patients admitted to 5 general medical-surgical floors at a 649-bed, tertiary care center in Boston, Massachusetts, were classified according to in-hospital antimicrobial exposure and MDRO colonization status. Within 48 hours of hospital admission (baseline) and at discharge (follow-up), rectal swab samples were obtained, and compared with samples from an external control group of healthy persons from the community. DNA was extracted from samples, next-generation sequencing performed, and microbial community structure and taxonomic features assessed, comparing those who acquired MDROs and those who had not, and the external controls.
RESULTS: Hospitalized patients (n = 44) had reduced microbial diversity and a greater abundance of Escherichia spp. and Enterococcus spp. than healthy controls (n = 26). Among hospitalized patients, 25 had no MDROs at the time of the baseline sample and were also exposed to antimicrobials. Among this group, 7 (28%) acquired ≥1 MDRO; demographic and clinical characteristics were similar between MDRO-acquisition and MDRO-nonacquisition groups. Patients in the nonacquisition group had consistently higher Lactobacillus spp. abundance than those in the acquisition group (linear discriminant score, 3.97; P = .04).
CONCLUSIONS: The fecal microbiota of the hospitalized subjects had abnormal community composition, and Lactobacillus spp. was associated with lack of MDRO acquisition, consistent with a protective role.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  acquisition; hospital; microbiome; multidrug-resistant organisms; risk factors

Mesh:

Substances:

Year:  2016        PMID: 27358350      PMCID: PMC5019285          DOI: 10.1093/cid/ciw426

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  38 in total

1.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

2.  Antibiotic resistance-the need for global solutions.

Authors:  Ramanan Laxminarayan; Adriano Duse; Chand Wattal; Anita K M Zaidi; Heiman F L Wertheim; Nithima Sumpradit; Erika Vlieghe; Gabriel Levy Hara; Ian M Gould; Herman Goossens; Christina Greko; Anthony D So; Maryam Bigdeli; Göran Tomson; Will Woodhouse; Eva Ombaka; Arturo Quizhpe Peralta; Farah Naz Qamar; Fatima Mir; Sam Kariuki; Zulfiqar A Bhutta; Anthony Coates; Richard Bergstrom; Gerard D Wright; Eric D Brown; Otto Cars
Journal:  Lancet Infect Dis       Date:  2013-11-17       Impact factor: 25.071

3.  Diagnostic accuracy of surveillance cultures to detect gastrointestinal colonization with multidrug-resistant gram-negative bacteria.

Authors:  Graham M Snyder; Erika M C D'Agata
Journal:  Am J Infect Control       Date:  2011-09-17       Impact factor: 2.918

4.  Intestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease.

Authors:  Robert R Jenq; Ying Taur; Sean M Devlin; Doris M Ponce; Jenna D Goldberg; Katya F Ahr; Eric R Littmann; Lilan Ling; Asia C Gobourne; Liza C Miller; Melissa D Docampo; Jonathan U Peled; Nicholas Arpaia; Justin R Cross; Tatanisha K Peets; Melissa A Lumish; Yusuke Shono; Jarrod A Dudakov; Hendrik Poeck; Alan M Hanash; Juliet N Barker; Miguel-Angel Perales; Sergio A Giralt; Eric G Pamer; Marcel R M van den Brink
Journal:  Biol Blood Marrow Transplant       Date:  2015-05-11       Impact factor: 5.742

Review 5.  The intestinal microbiota and susceptibility to infection in immunocompromised patients.

Authors:  Ying Taur; Eric G Pamer
Journal:  Curr Opin Infect Dis       Date:  2013-08       Impact factor: 4.915

Review 6.  Microbiota-mediated colonization resistance against intestinal pathogens.

Authors:  Charlie G Buffie; Eric G Pamer
Journal:  Nat Rev Immunol       Date:  2013-10-07       Impact factor: 53.106

7.  Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial.

Authors:  Marlene Wullt; Marie-Louise Johansson Hagslätt; Inga Odenholt
Journal:  Scand J Infect Dis       Date:  2003

8.  Metagenomic biomarker discovery and explanation.

Authors:  Nicola Segata; Jacques Izard; Levi Waldron; Dirk Gevers; Larisa Miropolsky; Wendy S Garrett; Curtis Huttenhower
Journal:  Genome Biol       Date:  2011-06-24       Impact factor: 13.583

9.  Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile.

Authors:  Charlie G Buffie; Vanni Bucci; Richard R Stein; Peter T McKenney; Lilan Ling; Asia Gobourne; Daniel No; Hui Liu; Melissa Kinnebrew; Agnes Viale; Eric Littmann; Marcel R M van den Brink; Robert R Jenq; Ying Taur; Chris Sander; Justin R Cross; Nora C Toussaint; Joao B Xavier; Eric G Pamer
Journal:  Nature       Date:  2014-10-22       Impact factor: 49.962

10.  Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment of C. difficile infection with oral vancomycin or metronidazole.

Authors:  Turki Abujamel; Jennifer L Cadnum; Lucy A Jury; Venkata C K Sunkesula; Sirisha Kundrapu; Robin L Jump; Alain C Stintzi; Curtis J Donskey
Journal:  PLoS One       Date:  2013-10-02       Impact factor: 3.240

View more
  15 in total

1.  Network of microbial and antibiotic interactions drive colonization and infection with multidrug-resistant organisms.

Authors:  Joyce Wang; Betsy Foxman; Lona Mody; Evan S Snitkin
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-12       Impact factor: 11.205

Review 2.  Clinical Practice and Infrastructure Review of Fecal Microbiota Transplantation for Clostridium difficile Infection.

Authors:  Brendan J Kelly; Pablo Tebas
Journal:  Chest       Date:  2017-09-18       Impact factor: 9.410

3.  Microbial Disruption Indices to Detect Colonization With Multidrug-Resistant Organisms.

Authors:  Rafael Araos; Veronica Montgomery; Juan A Ugalde; Graham M Snyder; Erika M C D'Agata
Journal:  Infect Control Hosp Epidemiol       Date:  2017-09-13       Impact factor: 3.254

4.  Gastrointestinal Microbiota Disruption and Risk of Colonization With Carbapenem-resistant Pseudomonas aeruginosa in Intensive Care Unit Patients.

Authors:  Melinda M Pettigrew; Janneane F Gent; Yong Kong; Alison Laufer Halpin; Lisa Pineles; Anthony D Harris; J Kristie Johnson
Journal:  Clin Infect Dis       Date:  2019-08-01       Impact factor: 9.079

5.  The Use of Microbiome Restoration Therapeutics to Eliminate Intestinal Colonization With Multidrug-Resistant Organisms.

Authors:  Srinivasa Nithin Gopalsamy; Michael H Woodworth; Tiffany Wang; Cynthia T Carpentieri; Nirja Mehta; Rachel J Friedman-Moraco; Aneesh K Mehta; Christian P Larsen; Colleen S Kraft
Journal:  Am J Med Sci       Date:  2018-08-29       Impact factor: 2.378

Review 6.  The potential role of microbiota for controlling the spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) in neonatal population.

Authors:  Thibaud Delerue; Loic de Pontual; Etienne Carbonnelle; Jean-Ralph Zahar
Journal:  F1000Res       Date:  2017-07-25

7.  Characterization of oral and gut microbiome temporal variability in hospitalized cancer patients.

Authors:  Jessica R Galloway-Peña; Daniel P Smith; Pranoti Sahasrabhojane; W Duncan Wadsworth; Bryan M Fellman; Nadim J Ajami; Elizabeth J Shpall; Naval Daver; Michele Guindani; Joseph F Petrosino; Dimitrios P Kontoyiannis; Samuel A Shelburne
Journal:  Genome Med       Date:  2017-02-28       Impact factor: 11.117

8.  Gut Microbiota and Clinical Features Distinguish Colonization With Klebsiella pneumoniae Carbapenemase-Producing Klebsiella pneumoniae at the Time of Admission to a Long-term Acute Care Hospital.

Authors:  Anna M Seekatz; Christine M Bassis; Louis Fogg; Nicholas M Moore; Yoona Rhee; Karen Lolans; Robert A Weinstein; Michael Y Lin; Vincent B Young; Mary K Hayden
Journal:  Open Forum Infect Dis       Date:  2018-07-31       Impact factor: 3.835

9.  Fecal Microbiome Characteristics and the Resistome Associated With Acquisition of Multidrug-Resistant Organisms Among Elderly Subjects.

Authors:  Rafael Araos; Thomas Battaglia; Juan A Ugalde; Marcelo Rojas-Herrera; Martin J Blaser; Erika M C D'Agata
Journal:  Front Microbiol       Date:  2019-09-27       Impact factor: 5.640

Review 10.  Gut Microbiota, Antibiotic Therapy and Antimicrobial Resistance: A Narrative Review.

Authors:  Benoit Pilmis; Alban Le Monnier; Jean-Ralph Zahar
Journal:  Microorganisms       Date:  2020-02-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.